DOCSLIB.ORG

( 12 ) United States Patent (10 ) Patent No.: US 10,682,400 B2 Ali Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
( 12 ) United States Patent (10 ) Patent No.: US 10,682,400 B2 Ali Et Al US010682400B2 ( 12 ) United States Patent (10 ) Patent No.: US 10,682,400 B2 Ali et al. (45 ) Date of Patent : Jun . 16 , 2020 ( 54 ) COMBINATION VACCINE DEVICES AND (2013.01 ) ; A61K 2039/55561 ( 2013.01) ; COOK METHODS OF KILLING CANCER CELLS 2317/21 (2013.01 ) ; CO7K 2317/24 (2013.01 ) (71 ) Applicants : President and Fellows of Harvard (58 ) Field of Classification Search College , Cambridge , MA (US ) ; CPC A61K 39/39 ; A61K 39/0011 Dana - Farber Cancer Institute , Inc., See application file for complete search history. Boston , MA (US ) (72 ) Inventors : Omar Abdel -Rahman Ali, Cambridge, ( 56 ) References Cited MA (US ) ; David J. Mooney, Sudbury, U.S. PATENT DOCUMENTS MA (US ) ; Glenn Dranoff , Lexington , MA (US ) 3,773,919 A 11/1973 Boswell et al . 4,522,811 A 6/1985 Eppstein et al . 4,946,778 A 8/1990 Ladner et al. ( 73 ) Assignees : President and Fellows of Harvard 5,073,627 A 12/1991 Curtis et al. College, Cambridge , MA (US ) ; 5,091,513 A 2/1992 Huston et al . Dana - Farber Cancer Institute , Inc. , 5,132,405 A 7/1992 Huston et al . Boston , MA (US ) 5,885,829 A 3/1999 Mooney et al . 5,888,987 A 3/1999 Haynes et al . 5,906,826 A 5/1999 Emery et al. ( * ) Notice: Subject to any disclaimer , the term of this 5,951,976 A 9/1999 Segal patent is extended or adjusted under 35 6,129,716 A 10/2000 Steer U.S.C. 154 ( b ) by 4 days . 6,193,970 B1 2/2001 Pardoll et al. 6,251,396 B1 6/2001 Gaur et al . (21 ) Appl. No .: 15 / 303,985 6,281,256 B1 8/2001 Harris et al. 6,334,968 B1 1/2002 Shapiro et al . (22 ) PCT Filed : Apr. 30 , 2015 6,352,694 B1 3/2002 June et al. 6,403,374 B1 6/2002 Tsien et al. 6,429,199 B1 8/2002 Krieg et al . ( 86 ) PCT No .: PCT/ US2015 /028468 6,511,511 B1 1/2003 Slivka et al . 6,511,650 B1 1/2003 Eiselt et al. $ 371 ( c ) ( 1 ) , 6,541,022 B1 4/2003 Murphy et al . (2 ) Date : Oct. 13 , 2016 6,642,363 B1 11/2003 Mooney et al. 6,685,963 B1 2/2004 Taupin et al. (87 ) PCT Pub . No .: WO2015 / 168379 6,748,954 B2 6/2004 Lee et al. PCT Pub . Date : Nov. 5 , 2015 ( Continued ) (65 ) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2017/0042995 A1 Feb. 16 , 2017 AU 2018201930 Al 4/2018 CN 1757662 A 4/2006 Related U.S. Application Data (Continued ) (60 ) Provisional application No.61 / 986,600 , filed on Apr. OTHER PUBLICATIONS 30 , 2014 . Hodi et al. ( N England J Med 2010 ; 363 :711-723 ) ( Year: 2010 ). * ( 51 ) Int. Cl. Quintana and Cohen ( J. Autoimmunity 2001 17 : 191-197 ) ( Year : A61K 39/00 ( 2006.01 ) 2001 ) . * COZK 16/28 (2006.01 ) Duraiswanny et al. ( Cancer Research Jun . 2013 73 ( 12 ) : 3591-3603 ) COOK 16:30 ( 2006.01 ) ( Year: 2013 ) . * A61K 39/12 ( 2006.01 ) (Continued ) A61K 39/39 ( 2006.01 ) A61K 39/395 ( 2006.01) A61K 47/34 ( 2017.01 ) Primary Examiner - Peter J Reddig A61K 4736 ( 2006.01 ) (74 ) Attorney , Agent, or Firm — McCarter & English , A61K 39/02 ( 2006.01) LLP ; Maria Laccotripe Zacharakis ; Maneesh Gulati C12N 7700 ( 2006.01) (52 ) U.S. CI. CPC A61K 39/0011 ( 2013.01 ) ; A61K 39/02 ( 57 ) ABSTRACT ( 2013.01 ); A61K 39/12 ( 2013.01 ) ; A61K 39/39 (2013.01 ) ; A61K 39/3955 ( 2013.01 ) ; A61K The present invention comprises compositions, methods, 47/34 ( 2013.01 ) ; A61K 47/36 (2013.01 ) ; CO7K and devices for enhancing an endogenous immune response 16/2803 ( 2013.01 ) ; CO7K 16/2818 ( 2013.01) ; against a cancer. Devices and methods provide therapeutic CO7K 16/30 (2013.01 ) ; CO7K 16/3053 immunity to subjects against cancer. ( 2013.01 ) ; C12N 7700 (2013.01 ) ; ACIK 2039/507 ( 2013.01 ) ; A61K 2039/5152 ( 2013.01) ; A61K 2039/54 (2013.01 ) ; A61K 26 Claims, 13 Drawing Sheets 2039/55516 (2013.01 ) ; A61K 2039/55522 Specification includes a Sequence Listing . US 10,682,400 B2 Page 2 ( 56 ) References Cited 2005/0154376 A1 7/2005 Riviere et al . 2005/0177249 A1 8/2005 Kladakis et al . U.S. PATENT DOCUMENTS 2005/0202394 Al 9/2005 Dobson 2006/0083712 A1 4/2006 Anversa 6,767,928 B1 7/2004 Murphy et al. 2006/0141018 Al 6/2006 Cochrum et al . 6,783,712 B2 8/2004 Slivka et al . 2006/0264380 A1 11/2006 Hellstrom et al . 6,790,840 B1 9/2004 Lee et al. 2006/0292134 Al 12/2006 Stohs 6,797,738 B2 9/2004 Harris et al. 2007/0003595 A1 1/2007 Wang et al . 6,800,733 B2 10/2004 Tsien et al. 2007/0020232 A1 1/2007 Rossignol et al . 6,858,222 B2 2/2005 Nelson et al. 2007/0026518 Al 2/2007 Healy et al . 6,974,698 B1 12/2005 Miller et al. 2007/0081972 Al 4/2007 Sandler et al . 7,015,205 B1 3/2006 Wallack et al. 2007/0116680 Al 5/2007 Stegemann et al . 7,157,566 B2 1/2007 Tsien et al. 2007/0178159 Al 8/2007 Chen et al . 7,186,413 B2 3/2007 Bouhadir et al . 2007/0190646 A1 8/2007 Engler et al . 7,192,693 B2 3/2007 Bryant et al. 2008/0044900 Al 2/2008 Mooney et al. 7,244,714 B1 7/2007 Gonda et al. 2008/0044990 A1 2/2008 Lee 7,410,953 B2 8/2008 Kawasaki 2008/0051490 A1 2/2008 Williams et al . 7,427,602 B1 9/2008 Shea et al. 2008/0113929 Al 5/2008 Lipford et al . 7,569,850 B2 8/2009 Noy et al . 2008/0138416 Al 6/2008 Rauh et al. 7,575,759 B2 8/2009 Murphy et al. 2008/0152624 Al 6/2008 Paludan et al . 7,592,326 B2 9/2009 Karaolis 2008/0206308 Al 8/2008 Jabbari et al. 7,687,241 B2 3/2010 Chen 2008/0233181 Al 9/2008 Nagy et al . 7,709,458 B2 5/2010 Karaolis et al. 2008/0268019 A1 10/2008 Badylak et al. 7,790,699 B2 9/2010 Melvik et al . 2008/0268052 Al 10/2008 Voytik - Harbin et al . 8,067,237 B2 11/2011 Mooney et al. 2009/0017096 Al 1/2009 Lowman et al. 8,188,058 B2 5/2012 Hackam et al. 2009/0061014 A1 3/2009 Messersmith et al. 8,273,373 B2 9/2012 Alsberg et al . 2009/0192079 Al 7/2009 Santos et al . 8,354,119 B2 1/2013 Geistlich et al. 2009/0238853 Al 9/2009 Liu et al. 8,367,628 B2 2/2013 Goodwin et al . 2009/0252752 Al 10/2009 Tahara et al . 8,535,719 B2 9/2013 Badylak et al. 2009/0297579 Al 12/2009 Semino et al. 8,709,464 B2 4/2014 Ma et al. 2009/0305983 A1 12/2009 Ying et al . 8,728,456 B2 5/2014 Sands et al . 2010/0015709 A1 1/2010 Rehfeldt et al. 8,883,308 B2 11/2014 Polshettiwar et al . 2010/0055102 Al 3/2010 Langermann 8,932,583 B2 1/2015 Mooney et al . 2010/0055186 A1 3/2010 Dadsetan et al. 9,012,399 B2 4/2015 Cao et al . 2010/0080816 A1 4/2010 Hadeiba et al. 9,132,210 B2 9/2015 Mooney et al. 2010/0129422 Al 5/2010 Han et al . 9,139,809 B2 9/2015 Porcelli et al . 2010/0159008 Al 6/2010 Barron et al. 9,150,631 B2 10/2015 Super et al . 2010/0189760 A1 7/2010 Schaffer et al . 9,370,558 B2 6/2016 Ali et al . 2010/0190741 A1 7/2010 Cohen et al. 9,381,235 B2 7/2016 Sands et al . 2010/0272771 Al 10/2010 Harlow et al . 9,446,107 B2 9/2016 Mooney et al . 2011/0008443 A1 1/2011 Alsberg et al . 9,486,512 B2 11/2016 Kim et al . 2011/0020216 A1 1/2011 Mooney et al . 9,591,360 B2 3/2017 Jennings et al. 2011/0117170 A1 5/2011 Cao et al. 9,675,561 B2 6/2017 Bencherif et al. 2011/0207166 A1 8/2011 Vaiselbuh 9,770,535 B2 9/2017 Mooney et al. 2011/0223255 Al 9/2011 Thiesen et al . 9,821,045 B2 11/2017 Ali et al . 2011/0253643 Al 10/2011 Polshettiwar et al . 9,937,249 B2 4/2018 Kim et al. 2011/0256184 A1 10/2011 Lei et al. 10,045,947 B2 8/2018 Bencherif et al. 2011/0300186 A1 12/2011 Hellstrom et al . 10,080,789 B2 9/2018 Sands et al . 2012/0100182 Al 4/2012 Mooney et al . 10,137,184 B2 11/2018 Mooney et al . 2012/0121539 Al 5/2012 Sands et al . 10,149,897 B2 12/2018 Mooney et al. 2012/0122218 Al 5/2012 Huebsch et al . 2002/0045672 A1 4/2002 Harris et al. 2012/0134967 A1 5/2012 Mooney et al. 2002/0131853 Al 9/2002 Nagasawa 2012/0256336 A1 10/2012 Yano et al. 2002/0131953 A1 9/2002 Takashima et al. 2012/0264599 Al 10/2012 Komatsu et al . 2002/0150604 A1 10/2002 Yi et al. 2012/0294888 Al 11/2012 Kishimoto et al. 2003/0075822 A1 4/2003 Slivka et al. 2012/0329791 Al 12/2012 Ashwell et al . 2003/0082806 Al 5/2003 Berenson et al.
Load more

Recommended publications
  • Cancer Immunity (1 December 2006) Vol
    Cancer Immun 1424-9634Academy of Cancer Immunology Cancer Immunity (1 December 2006) Vol. 6, p. 12 Submitted: 26 September 2006. Accepted: 10 October 2006. Copyright © 2006 by Andrew J. G. Simpson 061012 Article Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6) Hearn J. Cho1*,**, Otavia L. Caballero2*, Sacha Gnjatic2, Valéria C. C. Andrade3, Gisele W. Colleoni3, Andre L. Vettore4, Hasina H. Outtz1, Sheila Fortunato2, Nasser Altorki1, Cathy A. Ferrera1, Ramon Chua2, Achim A. Jungbluth2, Yao-Tseng Chen1, Lloyd J. Old2 and Andrew J. G. Simpson2 1Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA 2Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA 3Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil 4Ludwig Institute for Cancer Research, Sao Paulo Branch, Sao Paulo, SP, Brazil *These authors contributed equally to this work **Present address: NYU Cancer Institute, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA Contributed by: LJ Old Cancer/testis (CT) antigens are the protein products of germ line- encoded on the X chromosome (CT-X antigens) and those that associated genes that are activated in a wide variety of tumors and can are not (non-X CT antigens) (1). elicit autologous cellular and humoral immune responses. CT It is estimated that 10% of the genes on the X-chromosome antigens can be divided between those that are encoded on the X belong to CT-X families (5).
    [Show full text]
  • SS18 (SYT) (18Q11) Gene Rearrangement by FISH Indications for Ordering Genetics
    SS18 (SYT) (18q11) Gene Rearrangement by FISH Indications for Ordering Genetics Diagnosis of synovial sarcoma in conjunction with histologic Translocations – SS18-SSX1, SS18-SSX2 and clinical information Structure/function Test Description • SS18 is located on chromosome 18 • SSX1 and SSX2 are located on the X-chromosome Fluorescence in situ hybridization • Each gene in the translocation codes for proteins that have opposite transcriptional functions Tests to Consider o SS18 – activator of oncogenes Primary test o SSX1, SSX2 – tumor suppression SS18 (SYT) (18q11) Gene Rearrangement by FISH 3001303 Test Interpretation • Molecular diagnosis of synovial sarcoma Results Related test • Positive – SS18 rearrangement is detected Chromosome FISH, Interphase 2002298 o SSX translocation partner is not identified with this • Specific probe for SS18 (SYT) rearrangement must be testing methodology requested o Synovial sarcoma likely • Fresh tissue specimens only • Negative – no SS18 rearrangement detected Disease Overview o Does not entirely exclude the presence of an SS18 rearrangement as some translocations are cryptic and Incidence – rare not evaluable by this testing methodology • Synovial sarcomas account for 8-10% of all soft tissue o Does not entirely exclude diagnosis of synovial sarcoma sarcomas Limitations Diagnostic/prognostic issues • Testing using tissue fixed in alcohol-based or non-formalin • Synovial sarcomas may resemble other neoplasms, fixatives has not been validated using this method particularly those displaying an epithelioid, spindle cell, or • SS18 fusion partners are not detected with this test combined morphology • t(X;18)(p11.2;q11.2) translocation serves as a specific marker for synovial sarcoma o SS18 (SYT) gene fuses with SSX gene . Fusion with SSX1 in ~65% of synovial sarcomas .
    [Show full text]
  • Supplemental Materials Figure 1. 80 Genes Most Highly Differentially Expressed Comparing Dedifferentiated to Well- Differentiated Liposarcoma
    Supplemental Materials Figure 1. 80 genes most highly differentially expressed comparing dedifferentiated to well- differentiated liposarcoma Figure 2. Validation of microa CDC2, RACGAP1, FGFR-2, MAD2 and CITED1 200 CDK4 by Liposarcoma Subtype 16 0 12 0 80 Expression40 Level 0 Nl Fat rray data by quantitative RT-P Well Diff 16 0 p16 by Liposarcoma Subtype Dediff 12 0 80 Myxoid Expression40 Level Round Cell 0 12 0 MDM2 by Liposarcoma Subtype 10 0 Pleomorphic Nl Fat 80 60 40 Expression Level 20 RACGAP1 by LiposarcomaWell Diff Subtype 0 70 CR for genes CDK4, MDM2, p16, 60 Dediff 50 Nl Fat 40 30 Myxoid Expression20 Level Well Diff 10 50 0 Round Cell CDC2 by Liposarcoma Subtype Dediff 40 Nl Fat Pleomorphic 30 Myxoid 20 Expression Level Well Diff 10 MAD2L1 by Liposarcoma Subtype Round Cell 60 0 50 Dediff Pleomorphic 40 Nl Fat 30 Myxoid 20 Expression Level Well Diff 10 FGFR-2 by Liposarcoma Subtype 0 Round Cell 200 16 0 Dediff Nl Fat Pleomorphic 12 0 Myxoid 80 Expression Level Well Diff 40 Round Cell 0 Dediff Pleomorphic Nl Fat Myxoid Well Diff CITED1 by Liposarcoma Subtype Round Cell 10 0 80 Dediff Pleomorphic 60 40 Myxoid Expression Level 20 0 Round Cell Nl Fat Pleomorphic Well Diff Dediff Myxoid Round Cell Pleomorphic Table 1. 142 Gene classifier for liposarcoma subtype The genes used for each pair wise subtype comparison are grouped together. The flag column indicates which genes are unique to each subtype comparison. The values show the mean expression levels (actually the mean of the log expression levels was computed and than transformed back to absolute expression level).
    [Show full text]
  • Expression of Cancer-Testis Antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in Myxoid and Round Cell Liposarcoma
    Modern Pathology (2014) 27, 1238–1245 1238 & 2014 USCAP, Inc All rights reserved 0893-3952/14 $32.00 Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma Jessica A Hemminger1, Amanda Ewart Toland2, Thomas J Scharschmidt3, Joel L Mayerson3, Denis C Guttridge2 and O Hans Iwenofu1 1Department of Pathology and Laboratory Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH, USA; 2Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University Wexner Medical Center, Columbus, OH, USA and 3Department of Orthopedics, The Ohio State University Wexner Medical Center, Columbus, OH, USA Myxoid and round-cell liposarcoma is a frequently encountered liposarcoma subtype. The mainstay of treatment remains surgical excision with or without chemoradiation. However, treatment options are limited in the setting of metastatic disease. Cancer-testis antigens are immunogenic antigens with the expression largely restricted to testicular germ cells and various malignancies, making them attractive targets for cancer immunotherapy. Gene expression studies have reported the expression of various cancer-testis antigens in liposarcoma, with mRNA expression of CTAG1B, CTAG2, MAGEA9, and PRAME described specifically in myxoid and round-cell liposarcoma. Herein, we further explore the expression of the cancer-testis antigens MAGEA1, ACRBP, PRAME, and SSX2 in myxoid and round-cell liposarcoma by immunohistochemistry in addition to determining mRNA levels of CTAG2 (LAGE-1), PRAME, and MAGEA3 by quantitative real-time PCR. Samples in formalin-fixed paraffin-embedded blocks (n ¼ 37) and frozen tissue (n ¼ 8) were obtained for immunohistochemistry and quantitative real-time PCR, respectively. Full sections were stained with antibodies to MAGEA1, ACRBP, PRAME, and SSX2 and staining was assessed for intensity (1–2 þ ) and percent tumor positivity.
    [Show full text]
  • SYT-SSX1 and SYT-SSX2 Interfere with Repression of E-Cadherin by Snail and Slug
    Research Article SYT-SSX1 and SYT-SSX2 Interfere with Repression of E-Cadherin by Snail and Slug: A Potential Mechanism for Aberrant Mesenchymal to Epithelial Transition in Human Synovial Sarcoma Tsuyoshi Saito, Makoto Nagai, and Marc Ladanyi Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York Abstract open spaces [i.e., glandular epithelial differentiation (GED)] in a Synovial sarcoma is a primitive mesenchymal neoplasm background of spindle cells (Supplementary Fig. S1). Both the characterized in almost all cases by a t(X;18) fusing the SYT spindle and epithelial elements of synovial sarcoma contain transcriptional coactivator gene with either SSX1 or SSX2, the t(X;18) and are thus clonally related (2, 3). The GED in synovial with the resulting fusion gene encoding an aberrant tran- sarcoma has the hallmarks of a genuine mesenchymal to epithelial scriptional regulator.A subset of synovial sarcoma, predom- transition (MET) akin to those seen in embryonic development inantly cases with the SYT-SSX1 fusion, shows foci of (e.g., in developing kidney). Thus, the epithelial cells in synovial h morphologic epithelial differentiation in the form of nests of sarcoma express E-cadherin, keratins, a-catenin, -catenin, and glandular epithelium.The striking spontaneous mesenchymal g-catenin, whereas the spindle cells express vimentin and, focally, to epithelial differentiation in this cancer is reminiscent of a N-cadherin (4, 5). Epithelial differentiation in synovial sarcoma is developmental switch, but the only
    [Show full text]
  • A Novel Type of SYT/SSX Fusion
    A Novel Type of SYT/SSX Fusion: Methodological and Biological Implications Maria Törnkvist, M.Sc., Bertha Brodin, Ph.D., Armando Bartolazzi, M.D., Ph.D., Olle Larsson, M.D., Ph.D. Department of Cellular and Molecular Tumor Pathology, Cancer Centrum Karolinska, Karolinska Hospital (MT, BB, AB, OL), Stockholm, Sweden; and Department of Pathology, Regina Elena Cancer Institute (AB), Rome, Italy the presence of SYT/SSX transcripts in two cases Synovial sarcoma (SS) is a rare soft-tissue tumor using the proposed RT-PCR approach. Applications that affects children and young adults. It is charac- of optimized RT-PCR can contribute to reduce false- terized by the chromosomal translocation t(X; negative SYT/SSX SS cases reported in literature. 18)(p11.2;q11.2), which results in the fusion of the SYT gene on chromosome 18 with a SSX gene on KEY WORDS: RT-PCR, Synovial sarcoma, SYT/SSX chromosome X. In the majority of cases, SYT is fusion gene, SYT/SSX variants. fused to exon 5 of SSX1 (64%), SSX2 (36%), or, Mod Pathol 2002;15(6):679–685 rarely, SSX4. A novel fusion transcript variant deriv- ing from the fusion of SYT to exon 6 of SSX4 gene Synovial sarcomas (SS) account for 7 to 10% of all (SYT/SSX4v) was found coexpressed in one of the human soft-tissue sarcomas and are mainly located previously reported SYT/SSX4 cases. In the present in the extremities in the vicinity of large joints (1). investigation, we describe a new SS case that was Depending on histomorphological appearance, SSs previously shown to be negative for SYT/SSX1 and are usually subdivided into two major forms, bipha- SYT/SSX2 expression by conventional reverse tran- sic and monophasic.
    [Show full text]
  • Table S9: Summary of CN Loss Genes Identified by Fisher Test on ASCAT
    Table S9: Summary of CN Loss Genes identified by Fisher Test on ASCAT Gene Symbol Chromosome Start End Length FIGF chrX 15363712 15402535 38824 PIR-FIGF chrX 15363712 15509432 145721 PIR chrX 15402923 15511711 108789 BMX chrX 15518899 15574652 55754 ACE2 chrX 15579155 15620192 41038 TMEM27 chrX 15645440 15683154 37715 CA5BP1 chrX 15693038 15721474 28437 CA5B chrX 15756411 15805748 49338 INE2 chrX 15803838 15805712 1875 ZRSR2 chrX 15808573 15841382 32810 AP1S2 chrX 15843928 15873100 29173 GRPR chrX 16141423 16171641 30219 SUPT20HL1 chrX 24380877 24383541 2665 PDK3 chrX 24483343 24568583 85241 PCYT1B chrX 24576203 24690979 114777 SSX9 chrX 48160984 48165614 4631 SSX3 chrX 48205862 48216142 10281 SSX4B chrX 48242956 48252785 9830 SSX4 chrX 48242967 48252785 9819 SSX4 chrX 48261523 48271344 9822 SSX4B chrX 48261523 48271355 9833 SLC38A5 chrX 48316926 48328644 11719 FTSJ1 chrX 48334548 48344752 10205 PORCN chrX 48367370 48379202 11833 EBP chrX 48380163 48387104 6942 TBC1D25 chrX 48398074 48420997 22924 RBM3 chrX 48432740 48439553 6814 WDR13 chrX 48455879 48463582 7704 WAS chrX 48542185 48549817 7633 SUV39H1 chrX 48555130 48567406 12277 GLOD5 chrX 48620153 48632064 11912 GATA1 chrX 48644981 48652717 7737 HDAC6 chrX 48660486 48683380 22895 ERAS chrX 48684922 48688279 3358 PCSK1N chrX 48689503 48694036 4534 TIMM17B chrX 48750729 48755426 4698 PQBP1 chrX 48755194 48760422 5229 SLC35A2 chrX 48760458 48769235 8778 PIM2 chrX 48770458 48776413 5956 OTUD5 chrX 48779302 48815648 36347 KCND1 chrX 48818638 48828251 9614 GRIPAP1 chrX 48830133 48858675 28543
    [Show full text]
  • NY-ESO-1 (CTAG1B) Expression in Mesenchymal Tumors
    Modern Pathology (2015) 28, 587–595 & 2015 USCAP, Inc. All rights reserved 0893-3952/15 $32.00 587 NY-ESO-1 (CTAG1B) expression in mesenchymal tumors Makoto Endo1,2,7, Marieke A de Graaff3,7, Davis R Ingram4, Simin Lim1, Dina C Lev4, Inge H Briaire-de Bruijn3, Neeta Somaiah5, Judith VMG Bove´e3, Alexander J Lazar6 and Torsten O Nielsen1 1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada; 2Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan; 3Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; 4Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 5Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA and 6Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA New York esophageal squamous cell carcinoma 1 (NY-ESO-1, CTAG1B) is a cancer-testis antigen and currently a focus of several targeted immunotherapeutic strategies. We performed a large-scale immunohistochemical expression study of NY-ESO-1 using tissue microarrays of mesenchymal tumors from three institutions in an international collaboration. A total of 1132 intermediate and malignant and 175 benign mesenchymal lesions were enrolled in this study. Immunohistochemical staining was performed on tissue microarrays using a monoclonal antibody for NY-ESO-1. Among mesenchymal tumors, myxoid liposarcomas showed the highest positivity for NY-ESO-1 (88%), followed by synovial sarcomas (49%), myxofibrosarcomas (35%), and conventional chondrosarcomas (28%). Positivity of NY-ESO-1 in the remaining mesenchymal tumors was consistently low, and no immunoreactivity was observed in benign mesenchymal lesions.
    [Show full text]
  • A Novel FISH Assay for SS18–SSX Fusion Type in Synovial Sarcoma
    Laboratory Investigation (2004) 84, 1185–1192 & 2004 USCAP, Inc All rights reserved 0023-6837/04 $30.00 www.laboratoryinvestigation.org A novel FISH assay for SS18–SSX fusion type in synovial sarcoma Cecilia Surace1,2, Ioannis Panagopoulos1, Eva Pa˚lsson1, Mariano Rocchi2, Nils Mandahl1 and Fredrik Mertens1 1Department of Clinical Genetics, Lund University Hospital, Lund, Sweden and 2DAPEG, Section of Genetics, University of Bari, Bari, Italy Synovial sarcoma is a morphologically, clinically and genetically distinct entity that accounts for 5–10% of all soft tissue sarcomas. The t(X;18)(p11.2;q11.2) is the cytogenetic hallmark of synovial sarcoma and is present in more than 90% of the cases. It produces three types of fusion gene formed in part by SS18 from chromosome 18 and by SSX1, SSX2 or, rarely, SSX4 from the X chromosome. The SS18–SSX fusions do not seem to occur in other tumor types, and it has been shown that in synovial sarcoma a clear correlation exists between the type of fusion gene and histologic subtype and, more importantly, clinical outcome. Previous analyses regarding the type of fusion genes have been based on PCR amplification of the fusion transcript, requiring access to good- quality RNA. In order to obtain an alternative tool to diagnose and follow this malignancy, we developed a fluorescence in situ hybridization (FISH) assay that could distinguish between the two most common fusion genes, that is, SS18–SSX1 and SS18–SSX2. The specificity of the selected bacterial artificial chromosome clones used in the detection of these fusion genes, as well as the sensitivity of the analysis in metaphase and interphase cells, was examined in a series of 28 synovial sarcoma samples with known fusion gene status.
    [Show full text]
  • Gene Section Review
    Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Gene Section Review SSX2 (Synovial Sarcoma, X breakpoint 2) Josiane Eid, Christina Garcia, Andrea Frump Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA (JE, CG, AF) Published in Atlas Database: April 2008 Online updated version: http://AtlasGeneticsOncology.org/Genes/SSX2ID42406chXp11.html DOI: 10.4267/2042/44431 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2009 Atlas of Genetics and Cytogenetics in Oncology and Haematology detected in liver, testis, skin melanoma, endometrium, Identity choriocarcinoma, placenta, spleen of Hodgkins Other names: CT5.2; HD21; HOM-MEL-40; lymphoma. MGC119055; MGC15364; MGC3884; RP11-552J9.2; SSX; SSX2A; SSX2B Protein HGNC (Hugo): SSX2 Location: Xp11.22 Description So far, two SSX2 protein isoforms (a and b) are known DNA/RNA to exist. Their mRNAs correspond to SV1 (1466 bases) and SV3 (1322 bases) splice variants, respectively. The Description start codon for both isoforms is located in Exon 2. The SSX2 gene locus encompasses 9 exons and 10,304 SSX2 isoform a is 233 amino acids (26.5 kD) and bp (Xp11; 52,752,974-52,742,671). SSX2 isoform b 188 amino acids (21.6 kD). Of both isoforms, SSX2 isoform b is the most commonly seen Transcription and so far the best studied. The SSX2 gene is transcribed on the minus strand. 7 SSX2 mRNA splice variants (SV1-SV7) have been SSX2 Locus and mRNA Splice Variants. Note: Exons are drawn to scale. Atlas Genet Cytogenet Oncol Haematol.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.427,605 B2 Davis Et Al
    USOO7427605B2 (12) United States Patent (10) Patent No.: US 7.427,605 B2 Davis et al. (45) Date of Patent: Sep. 23, 2008 (54) INHIBITORS OF RIBONUCLEOTIDE 6,030,942 A 2/2000 Cooperman et al. REDUCTASE SUBUNIT 2 AND USES 7,056,704 B2 * 6/2006 Tuschl et al. ............... 435,911 THEREOF 7,098,030 B2 * 8/2006 Rozema et al. ............... 514,44 (75) Inventors: Mark E. Davis, Pasadena, CA (US); FOREIGN PATENT DOCUMENTS Jeremy D. Heidel, Pasadena, CA (US); WO WOO2,24864 3, 2002 John J. Rossi, Altaloma, CA (US) OTHER PUBLICATIONS (73) Assignee: Calando Pharmaceuticals, Inc., Cerqueria et al., 2005. Overview of ribonucleotide reductase inhibi Pasadena, CA (US) tors: an appealing target in anti-tumour therapy, Curr. Med. Chem. 12:1283. (*) Notice: Subject to any disclaimer, the term of this R.E.E. Aug 12, 2002, XPO024007222, database accession O. past lis listed under 35 Duxbury et al., 2004. Retrovirally mediated RNA interference tar M YW- y yS. geting the M2 Subunit of ribonucleotide reductase: A novel therapeu tic strategy in pancreatic cancer, Surgery 136:261-269. (21) Appl. No.: 11/396,365 Duxbury et al., 2004, RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma (22) Filed: Mar. 31, 2006 chemosensitivity to gemcitabine. Oncogene 28:1539-1548. Kim et al., 2002, Database EMBL, XPO02407223, Database acces (65) Prior Publication Data Sion No. BM754277. Kittler et al., 2004. An endoribonuclease-prepared siRNA screen in US 2006/0263.435A1 Nov. 23, 2006 human cells identifies genes essential for cell division, Nature O O 432:1036-1040.
    [Show full text]
  • Gene Expression Profiling Using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma Immunotherapy
    Published OnlineFirst September 10, 2013; DOI: 10.1158/1078-0432.CCR-13-1253 Clinical Cancer Human Cancer Biology Research Gene Expression Profiling using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma Immunotherapy Rachel E. Beard, Daniel Abate-Daga, Shannon F. Rosati, Zhili Zheng, John R. Wunderlich, Steven A. Rosenberg, and Richard A. Morgan Abstract Purpose: The success of immunotherapy for the treatment of metastatic cancer is contingent on the identification of appropriate target antigens. Potential targets must be expressed on tumors but show restricted expression on normal tissues. To maximize patient eligibility, ideal target antigens should be expressed on a high percentage of tumors within a histology and, potentially, in multiple different malignancies. Design: A Nanostring probeset was designed containing 97 genes, 72 of which are considered potential candidate genes for immunotherapy. Five established melanoma cell lines, 59 resected metastatic mela- noma tumors, and 31 normal tissue samples were profiled and analyzed using Nanostring technology. Results: Of the 72 potential target genes, 33 were overexpressed in more than 20% of studied melanoma tumor samples. Twenty of those genes were identified as differentially expressed between normal tissues and tumor samples by ANOVA analysis. Analysis of normal tissue gene expression identified seven genes with limited normal tissue expression that warrant further consideration as potential immunotherapy target antigens: CSAG2, MAGEA3, MAGEC2, IL13RA2, PRAME, CSPG4, and SOX10. These genes were highly overexpressed on a large percentage of the studied tumor samples, with expression in a limited number of normal tissue samples at much lower levels. Conclusion: The application of Nanostring RNA counting technology was used to directly quantitate the gene expression levels of multiple potential tumor antigens.
    [Show full text]